Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Stock Competitors & Peer Comparison

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, VRTX has a market cap of 127.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while VRTX trades at $502.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas VRTX's P/E ratio is 26.40. In terms of profitability, ALXN's ROE is +0.05%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ALXN is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check VRTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, REGN has a market cap of 76.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while REGN trades at $738.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas REGN's P/E ratio is 16.19. In terms of profitability, ALXN's ROE is +0.05%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALXN is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check REGN's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, MRNA has a market cap of 74.4B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while MRNA trades at $187.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas MRNA's P/E ratio is -23.00. In terms of profitability, ALXN's ROE is +0.05%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ALXN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check MRNA's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALXN's ROE is +0.05%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ALXN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check VRNA's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ARGX has a market cap of 57.9B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ARGX trades at $930.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ARGX's P/E ratio is 33.55. In terms of profitability, ALXN's ROE is +0.05%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ALXN is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ARGX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALXN's ROE is +0.05%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALXN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check SGEN's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RVMD has a market cap of 42.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RVMD trades at $199.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RVMD's P/E ratio is -22.66. In terms of profitability, ALXN's ROE is +0.05%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ALXN is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check RVMD's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RVMDW has a market cap of 42.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RVMDW trades at $10.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RVMDW's P/E ratio is -1.22. In terms of profitability, ALXN's ROE is +0.05%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ALXN is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check RVMDW's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ONC has a market cap of 38.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ONC trades at $362.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ONC's P/E ratio is 63.90. In terms of profitability, ALXN's ROE is +0.05%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ALXN is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ONC's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ALNY has a market cap of 30B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ALNY trades at $223.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ALNY's P/E ratio is 40.35. In terms of profitability, ALXN's ROE is +0.05%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ALXN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ALNY's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ROIV has a market cap of 25.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ROIV trades at $35.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ROIV's P/E ratio is -33.80. In terms of profitability, ALXN's ROE is +0.05%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ALXN is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ROIV's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, BNTX has a market cap of 24B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while BNTX trades at $95.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas BNTX's P/E ratio is -12.41. In terms of profitability, ALXN's ROE is +0.05%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ALXN is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check BNTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, GMAB has a market cap of 23.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while GMAB trades at $37.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas GMAB's P/E ratio is 28.49. In terms of profitability, ALXN's ROE is +0.05%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ALXN is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check GMAB's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while UTHR trades at $541.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas UTHR's P/E ratio is 19.38. In terms of profitability, ALXN's ROE is +0.05%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ALXN is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check UTHR's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, INCY has a market cap of 22.9B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while INCY trades at $112.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas INCY's P/E ratio is 15.15. In terms of profitability, ALXN's ROE is +0.05%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ALXN is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check INCY's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, INSM has a market cap of 22.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while INSM trades at $105.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas INSM's P/E ratio is -25.60. In terms of profitability, ALXN's ROE is +0.05%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ALXN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check INSM's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALXN's ROE is +0.05%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ALXN is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check BGNE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALXN's ROE is +0.05%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ALXN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check DNA-WT's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while EXEL trades at $58.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas EXEL's P/E ratio is 16.67. In terms of profitability, ALXN's ROE is +0.05%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ALXN is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check EXEL's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, NBIX has a market cap of 14.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while NBIX trades at $145.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas NBIX's P/E ratio is 21.03. In terms of profitability, ALXN's ROE is +0.05%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ALXN is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check NBIX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while JAZZ trades at $231.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas JAZZ's P/E ratio is 8.63. In terms of profitability, ALXN's ROE is +0.05%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ALXN is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check JAZZ's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ASND has a market cap of 14B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ASND trades at $226.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ASND's P/E ratio is -93.41. In terms of profitability, ALXN's ROE is +0.05%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ALXN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ASND's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, SMMT has a market cap of 13.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while SMMT trades at $17.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas SMMT's P/E ratio is -15.46. In terms of profitability, ALXN's ROE is +0.05%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ALXN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check SMMT's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while BBIO trades at $66.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas BBIO's P/E ratio is -17.90. In terms of profitability, ALXN's ROE is +0.05%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ALXN is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check BBIO's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, HALO has a market cap of 13B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while HALO trades at $109.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas HALO's P/E ratio is 20.47. In terms of profitability, ALXN's ROE is +0.05%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ALXN is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check HALO's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALXN's ROE is +0.05%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALXN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check KRTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while MDGL trades at $496.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas MDGL's P/E ratio is -38.79. In terms of profitability, ALXN's ROE is +0.05%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ALXN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check MDGL's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TECH trades at $72.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TECH's P/E ratio is 37.34. In terms of profitability, ALXN's ROE is +0.05%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ALXN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check TECH's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALXN's ROE is +0.05%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ALXN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check RNAM's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while BMRN trades at $56.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas BMRN's P/E ratio is 27.03. In terms of profitability, ALXN's ROE is +0.05%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ALXN is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check BMRN's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TWST trades at $166.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TWST's P/E ratio is -75.21. In terms of profitability, ALXN's ROE is +0.05%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ALXN is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check TWST's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TXG has a market cap of 10.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TXG trades at $80.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TXG's P/E ratio is -136.71. In terms of profitability, ALXN's ROE is +0.05%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ALXN is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check TXG's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, IBRX has a market cap of 10.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while IBRX trades at $9.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas IBRX's P/E ratio is -9.99. In terms of profitability, ALXN's ROE is +0.05%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ALXN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check IBRX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while KRYS trades at $326.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas KRYS's P/E ratio is 40.95. In terms of profitability, ALXN's ROE is +0.05%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALXN is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check KRYS's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, PCVX has a market cap of 9.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while PCVX trades at $66.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas PCVX's P/E ratio is -8.72. In terms of profitability, ALXN's ROE is +0.05%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ALXN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check PCVX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALXN's ROE is +0.05%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALXN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check RXDX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ALXN's ROE is +0.05%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALXN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check NUVL's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ALXN's ROE is +0.05%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALXN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check CRNX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, AXSM has a market cap of 9B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while AXSM trades at $174.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas AXSM's P/E ratio is -45.52. In terms of profitability, ALXN's ROE is +0.05%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ALXN is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check AXSM's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, PTGX has a market cap of 8.9B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while PTGX trades at $138.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas PTGX's P/E ratio is 134.65. In terms of profitability, ALXN's ROE is +0.05%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ALXN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check PTGX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALXN's ROE is +0.05%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALXN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check IMGN's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, KYMR has a market cap of 8.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while KYMR trades at $105.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas KYMR's P/E ratio is -33.12. In terms of profitability, ALXN's ROE is +0.05%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ALXN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check KYMR's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ARWR has a market cap of 8.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ARWR trades at $61.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ARWR's P/E ratio is -27.35. In terms of profitability, ALXN's ROE is +0.05%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ALXN is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ARWR's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALXN's ROE is +0.05%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ALXN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check BPMC's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas APGE's P/E ratio is -31.19. In terms of profitability, ALXN's ROE is +0.05%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ALXN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check APGE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALXN's ROE is +0.05%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALXN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check CERE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TGTX trades at $52.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TGTX's P/E ratio is 18.91. In terms of profitability, ALXN's ROE is +0.05%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ALXN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check TGTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while PRAX trades at $280.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas PRAX's P/E ratio is -21.69. In terms of profitability, ALXN's ROE is +0.05%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ALXN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check PRAX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CAI has a market cap of 7.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CAI trades at $27.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CAI's P/E ratio is 77.14. In terms of profitability, ALXN's ROE is +0.05%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ALXN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check CAI's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CYTK has a market cap of 7.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CYTK trades at $61.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CYTK's P/E ratio is -8.50. In terms of profitability, ALXN's ROE is +0.05%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ALXN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check CYTK's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALXN's ROE is +0.05%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ALXN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check MTSR's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, IONS has a market cap of 7.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while IONS trades at $44.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas IONS's P/E ratio is -13.46. In terms of profitability, ALXN's ROE is +0.05%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ALXN is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check IONS's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, SYRE has a market cap of 7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while SYRE trades at $80.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas SYRE's P/E ratio is -41.08. In terms of profitability, ALXN's ROE is +0.05%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ALXN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check SYRE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALXN's ROE is +0.05%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ALXN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check MRUS's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALXN's ROE is +0.05%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALXN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check ACLX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, IMVT has a market cap of 6.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while IMVT trades at $32.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas IMVT's P/E ratio is -11.39. In terms of profitability, ALXN's ROE is +0.05%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ALXN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check IMVT's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALXN's ROE is +0.05%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALXN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check RETA's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ABVX trades at $88.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ABVX's P/E ratio is -14.45. In terms of profitability, ALXN's ROE is +0.05%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ALXN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ABVX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ALXN's ROE is +0.05%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALXN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check CNTA's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while BLTE trades at $155.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas BLTE's P/E ratio is -83.21. In terms of profitability, ALXN's ROE is +0.05%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ALXN is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check BLTE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RYTM trades at $90.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RYTM's P/E ratio is -29.19. In terms of profitability, ALXN's ROE is +0.05%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ALXN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check RYTM's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while LGND trades at $296.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas LGND's P/E ratio is 32.59. In terms of profitability, ALXN's ROE is +0.05%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ALXN is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check LGND's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, IOVA has a market cap of 5.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while IOVA trades at $12.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas IOVA's P/E ratio is -17.75. In terms of profitability, ALXN's ROE is +0.05%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ALXN is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check IOVA's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, KOD has a market cap of 5.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while KOD trades at $92.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas KOD's P/E ratio is -22.14. In terms of profitability, ALXN's ROE is +0.05%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ALXN is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check KOD's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALXN's ROE is +0.05%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ALXN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check CDTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CGON trades at $63.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CGON's P/E ratio is -23.66. In terms of profitability, ALXN's ROE is +0.05%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ALXN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check CGON's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALXN's ROE is +0.05%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALXN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check ABCM's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALXN's ROE is +0.05%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALXN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check ISEE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while PTCT trades at $63.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas PTCT's P/E ratio is -27.34. In terms of profitability, ALXN's ROE is +0.05%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ALXN is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check PTCT's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALXN's ROE is +0.05%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALXN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check APLS's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CRSP trades at $54.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CRSP's P/E ratio is -11.34. In terms of profitability, ALXN's ROE is +0.05%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ALXN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check CRSP's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TVTX trades at $55.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TVTX's P/E ratio is -124.40. In terms of profitability, ALXN's ROE is +0.05%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ALXN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check TVTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, COGT has a market cap of 5.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while COGT trades at $30.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas COGT's P/E ratio is -14.40. In terms of profitability, ALXN's ROE is +0.05%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ALXN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check COGT's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while SRRK trades at $42.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas SRRK's P/E ratio is -12.30. In terms of profitability, ALXN's ROE is +0.05%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ALXN is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check SRRK's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ERAS trades at $14.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ERAS's P/E ratio is -15.38. In terms of profitability, ALXN's ROE is +0.05%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ALXN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ERAS's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ORKA has a market cap of 4.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ORKA trades at $80.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ORKA's P/E ratio is -41.33. In terms of profitability, ALXN's ROE is +0.05%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ALXN is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ORKA's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while MIRM trades at $79.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas MIRM's P/E ratio is -5.45. In terms of profitability, ALXN's ROE is +0.05%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ALXN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check MIRM's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, DNTH has a market cap of 4.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while DNTH trades at $85.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas DNTH's P/E ratio is -20.58. In terms of profitability, ALXN's ROE is +0.05%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ALXN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check DNTH's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALXN's ROE is +0.05%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALXN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check TERN's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while DFTX trades at $35.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas DFTX's P/E ratio is N/A. In terms of profitability, ALXN's ROE is +0.05%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ALXN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check DFTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALXN's ROE is +0.05%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ALXN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check FOLD's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while MANE trades at $108.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas MANE's P/E ratio is -34.63. In terms of profitability, ALXN's ROE is +0.05%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ALXN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check MANE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALXN's ROE is +0.05%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ALXN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check AKRO's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALXN's ROE is +0.05%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALXN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check ALPN's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while EWTX trades at $40.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas EWTX's P/E ratio is -21.63. In terms of profitability, ALXN's ROE is +0.05%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ALXN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check EWTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ADPT has a market cap of 4.3B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ADPT trades at $26.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ADPT's P/E ratio is -65.61. In terms of profitability, ALXN's ROE is +0.05%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ALXN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ADPT's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALXN's ROE is +0.05%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ALXN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check OPT's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ALXN's ROE is +0.05%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ALXN is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check PRTC's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALXN's ROE is +0.05%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALXN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check MRTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RLAY trades at $18.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RLAY's P/E ratio is -11.94. In terms of profitability, ALXN's ROE is +0.05%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ALXN is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check RLAY's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, ABCL has a market cap of 4B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while ABCL trades at $13.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas ABCL's P/E ratio is -24.35. In terms of profitability, ALXN's ROE is +0.05%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ALXN is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check ABCL's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ALXN's ROE is +0.05%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALXN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check CPRX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALXN's ROE is +0.05%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALXN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check RYZB's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALXN's ROE is +0.05%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALXN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check CBAY's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TLX trades at $10.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TLX's P/E ratio is 112.53. In terms of profitability, ALXN's ROE is +0.05%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ALXN is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check TLX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while TNGX trades at $21.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas TNGX's P/E ratio is -26.39. In terms of profitability, ALXN's ROE is +0.05%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ALXN is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check TNGX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ALXN's ROE is +0.05%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ALXN is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ALXN.Check SWTX's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, XENE has a market cap of 3.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while XENE trades at $36.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas XENE's P/E ratio is -7.78. In terms of profitability, ALXN's ROE is +0.05%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ALXN is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check XENE's competition here

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALXN stands at 0. In comparison, IDYA has a market cap of 3.5B. Regarding current trading prices, ALXN is priced at $182.50 on the NASDAQ, while IDYA trades at $36.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALXN currently has a P/E ratio of 59.23, whereas IDYA's P/E ratio is -18.88. In terms of profitability, ALXN's ROE is +0.05%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, ALXN is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for ALXN.Check IDYA's competition here